miR-126 in human cancers: Clinical roles and current perspectives
miR-126 has been implicated in the processes of inflammation and angiogenesis. Through these processes, miR-126 is implicated in cancer biology, but its role there has not been well reviewed. The aim of this review is to examine the molecular mechanisms and clinicopathological significance of miR-12...
Saved in:
| Published in | Experimental and molecular pathology Vol. 96; no. 1; pp. 98 - 107 |
|---|---|
| Main Authors | , , , |
| Format | Journal Article |
| Language | English |
| Published |
Netherlands
Elsevier Inc
01.02.2014
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0014-4800 1096-0945 1096-0945 |
| DOI | 10.1016/j.yexmp.2013.12.004 |
Cover
Loading…
| Abstract | miR-126 has been implicated in the processes of inflammation and angiogenesis. Through these processes, miR-126 is implicated in cancer biology, but its role there has not been well reviewed. The aim of this review is to examine the molecular mechanisms and clinicopathological significance of miR-126 in human cancers. miR-126 was shown to have roles in cancers of the gastrointestinal tract, genital tracts, breast, thyroid, lung and some other cancers. Its expression was suppressed in most of the cancers studied. The molecular mechanisms that are known to cause aberrant expression of miR-126 include alterations in gene sequence, epigenetic modification and alteration of dicer abundance. miR-126 can inhibit progression of some cancers via negative control of proliferation, migration, invasion, and cell survival. In some instances, however, miR-126 supports cancer progression via promotion of blood vessel formation. Downregulation of miR-126 induces cancer cell proliferation, migration, and invasion via targeting specific oncogenes. Also, reduced levels of miR-126 are a significant predictor of poor survival of patients in many cancers. In addition, miR-126 can alter a multitude of cellular mechanisms in cancer pathogenesis via suppressing gene translation of numerous validated targets such as PI3K, KRAS, EGFL7, CRK, ADAM9, HOXA9, IRS-1, SOX-2, SLC7A5 and VEGF. To conclude, miR-126 is commonly down-regulated in cancer, most likely due to its ability to inhibit cancer cell growth, adhesion, migration, and invasion through suppressing a range of important gene targets. Understanding these mechanisms by which miR-126 is involved with cancer pathogenesis will be useful in the development of therapeutic targets for the management of patients with cancer. |
|---|---|
| AbstractList | miR-126 has been implicated in the processes of inflammation and angiogenesis. Through these processes, miR-126 is implicated in cancer biology, but its role there has not been well reviewed. The aim of this review is to examine the molecular mechanisms and clinicopathological significance of miR-126 in human cancers. miR-126 was shown to have roles in cancers of the gastrointestinal tract, genital tracts, breast, thyroid, lung and some other cancers. Its expression was suppressed in most of the cancers studied. The molecular mechanisms that are known to cause aberrant expression of miR-126 include alterations in gene sequence, epigenetic modification and alteration of dicer abundance. miR-126 can inhibit progression of some cancers via negative control of proliferation, migration, invasion, and cell survival. In some instances, however, miR-126 supports cancer progression via promotion of blood vessel formation. Downregulation of miR-126 induces cancer cell proliferation, migration, and invasion via targeting specific oncogenes. Also, reduced levels of miR-126 are a significant predictor of poor survival of patients in many cancers. In addition, miR-126 can alter a multitude of cellular mechanisms in cancer pathogenesis via suppressing gene translation of numerous validated targets such as PI3K, KRAS, EGFL7, CRK, ADAM9, HOXA9, IRS-1, SOX-2, SLC7A5 and VEGF. To conclude, miR-126 is commonly down-regulated in cancer, most likely due to its ability to inhibit cancer cell growth, adhesion, migration, and invasion through suppressing a range of important gene targets. Understanding these mechanisms by which miR-126 is involved with cancer pathogenesis will be useful in the development of therapeutic targets for the management of patients with cancer. miR-126 has been implicated in the processes of inflammation and angiogenesis. Through these processes, miR-126 is implicated in cancer biology, but its role there has not been well reviewed. The aim of this review is to examine the molecular mechanisms and clinicopathological significance of miR-126 in human cancers. miR-126 was shown to have roles in cancers of the gastrointestinal tract, genital tracts, breast, thyroid, lung and some other cancers. Its expression was suppressed in most of the cancers studied. The molecular mechanisms that are known to cause aberrant expression of miR-126 include alterations in gene sequence, epigenetic modification and alteration of dicer abundance. miR-126 can inhibit progression of some cancers via negative control of proliferation, migration, invasion, and cell survival. In some instances, however, miR-126 supports cancer progression via promotion of blood vessel formation. Downregulation of miR-126 induces cancer cell proliferation, migration, and invasion via targeting specific oncogenes. Also, reduced levels of miR-126 are a significant predictor of poor survival of patients in many cancers. In addition, miR-126 can alter a multitude of cellular mechanisms in cancer pathogenesis via suppressing gene translation of numerous validated targets such as PI3K, KRAS, EGFL7, CRK, ADAM9, HOXA9, IRS-1, SOX-2, SLC7A5 and VEGF. To conclude, miR-126 is commonly down-regulated in cancer, most likely due to its ability to inhibit cancer cell growth, adhesion, migration, and invasion through suppressing a range of important gene targets. Understanding these mechanisms by which miR-126 is involved with cancer pathogenesis will be useful in the development of therapeutic targets for the management of patients with cancer.miR-126 has been implicated in the processes of inflammation and angiogenesis. Through these processes, miR-126 is implicated in cancer biology, but its role there has not been well reviewed. The aim of this review is to examine the molecular mechanisms and clinicopathological significance of miR-126 in human cancers. miR-126 was shown to have roles in cancers of the gastrointestinal tract, genital tracts, breast, thyroid, lung and some other cancers. Its expression was suppressed in most of the cancers studied. The molecular mechanisms that are known to cause aberrant expression of miR-126 include alterations in gene sequence, epigenetic modification and alteration of dicer abundance. miR-126 can inhibit progression of some cancers via negative control of proliferation, migration, invasion, and cell survival. In some instances, however, miR-126 supports cancer progression via promotion of blood vessel formation. Downregulation of miR-126 induces cancer cell proliferation, migration, and invasion via targeting specific oncogenes. Also, reduced levels of miR-126 are a significant predictor of poor survival of patients in many cancers. In addition, miR-126 can alter a multitude of cellular mechanisms in cancer pathogenesis via suppressing gene translation of numerous validated targets such as PI3K, KRAS, EGFL7, CRK, ADAM9, HOXA9, IRS-1, SOX-2, SLC7A5 and VEGF. To conclude, miR-126 is commonly down-regulated in cancer, most likely due to its ability to inhibit cancer cell growth, adhesion, migration, and invasion through suppressing a range of important gene targets. Understanding these mechanisms by which miR-126 is involved with cancer pathogenesis will be useful in the development of therapeutic targets for the management of patients with cancer. |
| Author | Ebrahimi, Faeza Gopalan, Vinod Lam, Alfred King-Yin Smith, Robert Anthony |
| Author_xml | – sequence: 1 givenname: Faeza surname: Ebrahimi fullname: Ebrahimi, Faeza – sequence: 2 givenname: Vinod surname: Gopalan fullname: Gopalan, Vinod – sequence: 3 givenname: Robert Anthony surname: Smith fullname: Smith, Robert Anthony – sequence: 4 givenname: Alfred King-Yin surname: Lam fullname: Lam, Alfred King-Yin email: a.lam@griffith.edu.au |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/24368110$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkMFL5DAUh8PisjPq_gWC9Oil9b0kzaSCBxlcFYQFmXvIpG8wQ5vWpBXnv7fuuB486Oldvu8H7ztkB6ELxNgJQoGA6nxb7Oil7QsOKArkBYD8weYIlcqhkuUBmwOgzKUGmLHDlLYAUAHyX2zGpVAaEebsqvUPOXKV-ZA9jq0NmbPBUUwX2bLxwTvbZLFrKGU21JkbY6QwZP0E9OQG_0zpmP3c2CbR7_d7xFZ_rlfL2_z-783d8uo-d5KXQy5RVeSUlBbrCmGN6w1flKVY8I0StZDWKqpQSlC6FmAtotKSnCBday20OGJn-9k-dk8jpcG0PjlqGhuoG5PBElFzXJR8Qk_f0XHdUm366Fsbd-b_1xMg9oCLXUqRNh8Ignlra7bmX1vz1tYgN1Pbyao-Wc4PdvBdGKL1zTfu5d6lqdCzp2iS8zSFrn2cOpq681_6rxluk4w |
| CitedBy_id | crossref_primary_10_1016_j_bmcl_2016_10_042 crossref_primary_10_1111_1759_7714_13020 crossref_primary_10_1186_1472_6890_14_45 crossref_primary_10_18632_oncotarget_8314 crossref_primary_10_1007_s13105_024_01017_y crossref_primary_10_1016_j_lfs_2015_04_016 crossref_primary_10_1016_j_rbmo_2015_05_016 crossref_primary_10_3390_ijms17020156 crossref_primary_10_1002_iub_1926 crossref_primary_10_1007_s12033_023_00977_8 crossref_primary_10_18632_oncotarget_4351 crossref_primary_10_3390_ijms221910465 crossref_primary_10_1016_j_yexcr_2015_10_004 crossref_primary_10_1016_j_yexcr_2018_06_025 crossref_primary_10_1164_rccm_201706_1304LE crossref_primary_10_1016_j_lfs_2019_04_023 crossref_primary_10_1016_j_cca_2024_117824 crossref_primary_10_1002_jcp_31084 crossref_primary_10_2174_2772432817666220520085719 crossref_primary_10_1186_s12896_018_0423_4 crossref_primary_10_1007_s11033_022_07126_5 crossref_primary_10_1371_journal_pone_0134220 crossref_primary_10_1186_s12917_016_0903_5 crossref_primary_10_1016_j_omto_2021_04_002 crossref_primary_10_1002_jcb_28111 crossref_primary_10_1038_onc_2015_357 crossref_primary_10_1530_JME_15_0182 crossref_primary_10_1155_2014_372901 crossref_primary_10_1136_jclinpath_2016_203972 crossref_primary_10_1186_s12885_018_4801_z crossref_primary_10_1016_j_canlet_2017_02_025 crossref_primary_10_1016_j_yexmp_2015_03_002 crossref_primary_10_1134_S1022795421060107 crossref_primary_10_1007_s11095_014_1497_x crossref_primary_10_1161_ATVBAHA_115_306094 crossref_primary_10_1111_boc_201500062 crossref_primary_10_3389_fcvm_2022_879351 crossref_primary_10_1016_j_cllc_2016_03_012 crossref_primary_10_1007_s10529_020_02864_7 crossref_primary_10_3892_or_2015_3839 crossref_primary_10_1007_s13277_014_2588_3 crossref_primary_10_1016_j_mce_2017_03_015 crossref_primary_10_18632_oncotarget_17283 crossref_primary_10_1002_med_21452 crossref_primary_10_1007_s12035_015_9654_8 crossref_primary_10_1155_2015_739469 crossref_primary_10_1158_1055_9965_EPI_18_0453 crossref_primary_10_3390_cancers15010111 crossref_primary_10_1007_s10528_024_11012_z crossref_primary_10_1038_s41598_021_87985_3 crossref_primary_10_1007_s13277_015_4374_2 crossref_primary_10_1186_s12885_021_08743_2 crossref_primary_10_3892_mmr_2018_8459 crossref_primary_10_18632_oncotarget_15706 crossref_primary_10_3892_ijo_2016_3435 crossref_primary_10_1177_1010428317709128 crossref_primary_10_17116_oftalma20241400315 crossref_primary_10_1016_j_yexcr_2015_09_010 crossref_primary_10_1016_j_carbpol_2022_119489 crossref_primary_10_1007_s11033_021_06322_z crossref_primary_10_1016_j_yjmcc_2016_05_007 crossref_primary_10_1016_j_semcancer_2019_03_004 crossref_primary_10_3389_fonc_2019_01293 crossref_primary_10_1152_ajpcell_00459_2019 crossref_primary_10_1080_01635581_2021_1936082 crossref_primary_10_1155_2019_1342161 crossref_primary_10_1021_acs_biochem_0c00141 crossref_primary_10_1097_JOM_0000000000000742 crossref_primary_10_1016_j_critrevonc_2016_04_006 crossref_primary_10_3390_biomedicines11030801 crossref_primary_10_1007_s40618_014_0234_y crossref_primary_10_1096_fj_202301836R crossref_primary_10_1155_2015_823620 crossref_primary_10_3389_fonc_2022_956225 crossref_primary_10_1016_j_biocel_2020_105700 crossref_primary_10_1002_ijc_30895 crossref_primary_10_3892_ol_2018_9639 crossref_primary_10_18632_oncotarget_9686 crossref_primary_10_3389_fpubh_2017_00077 crossref_primary_10_18632_oncotarget_15608 crossref_primary_10_3390_diagnostics12030745 crossref_primary_10_1002_cbin_10572 crossref_primary_10_1134_S0006297915020029 crossref_primary_10_3390_cancers10080261 crossref_primary_10_1186_s12917_021_02929_3 crossref_primary_10_3390_ijms22126337 crossref_primary_10_1007_s00432_018_2586_8 crossref_primary_10_1186_s41065_019_0087_7 crossref_primary_10_1016_j_yexcr_2017_05_021 crossref_primary_10_1016_j_yexmp_2015_08_013 crossref_primary_10_1080_1061186X_2023_2284097 crossref_primary_10_3892_or_2015_4165 crossref_primary_10_1089_nat_2014_0501 crossref_primary_10_3390_ijms26010328 crossref_primary_10_1007_s12032_014_0221_3 crossref_primary_10_1007_s12291_018_0766_6 crossref_primary_10_1159_000518722 crossref_primary_10_18632_oncotarget_8916 crossref_primary_10_2217_pme_2016_0020 crossref_primary_10_1111_jvim_14602 crossref_primary_10_1134_S1990750824600869 crossref_primary_10_23736_S1825_859X_23_00194_9 crossref_primary_10_1093_nar_gkx858 crossref_primary_10_1073_pnas_2105428118 crossref_primary_10_3390_microorganisms9061339 crossref_primary_10_1186_1476_4598_13_169 crossref_primary_10_1016_j_yexmp_2014_08_002 crossref_primary_10_1128_IAI_00263_16 crossref_primary_10_1161_ATVBAHA_119_313800 crossref_primary_10_1186_s12964_024_01936_9 crossref_primary_10_3390_ijms161126001 crossref_primary_10_3390_pharmaceutics16080986 crossref_primary_10_1016_j_yexcr_2016_09_010 crossref_primary_10_1186_s12885_024_12893_4 crossref_primary_10_3892_ol_2016_5250 crossref_primary_10_2174_1568009618666180628154727 crossref_primary_10_18632_oncotarget_19495 crossref_primary_10_1038_s41598_017_15475_6 crossref_primary_10_1186_s11658_016_0004_2 crossref_primary_10_3390_ijms22073640 crossref_primary_10_3892_ijo_2022_5395 crossref_primary_10_18632_oncotarget_2284 crossref_primary_10_3892_ol_2018_8778 crossref_primary_10_1186_s12967_014_0254_6 crossref_primary_10_1007_s10689_015_9846_4 crossref_primary_10_1016_j_esmoop_2023_101573 crossref_primary_10_1186_s13046_019_1238_4 crossref_primary_10_1016_j_ajpath_2014_11_017 crossref_primary_10_1007_s00432_018_2767_5 crossref_primary_10_1007_s00018_018_2796_x crossref_primary_10_1515_hsz_2023_0358 crossref_primary_10_1016_j_yexcr_2014_08_006 |
| Cites_doi | 10.1016/j.urolonc.2009.01.027 10.1186/1476-4598-8-102 10.1016/j.bbrc.2008.06.090 10.1080/00313020802320713 10.1016/j.cca.2010.05.002 10.1371/journal.pone.0056824 10.1007/s11010-011-0723-7 10.1007/s11010-013-1707-6 10.1016/j.molonc.2011.06.003 10.1007/s00384-009-0862-4 10.1038/bjc.2011.401 10.1093/abbs/gms026 10.1038/nature06487 10.1016/j.ygyno.2008.08.036 10.1371/journal.pone.0032068 10.1016/j.lungcan.2009.01.010 10.1016/j.canep.2012.07.002 10.1245/s10434-011-1766-4 10.1038/bjc.2012.330 10.1016/j.surg.2008.07.027 10.1158/1078-0432.CCR-05-0646 10.1038/onc.2013.335 10.1016/j.eururo.2011.01.004 10.1371/journal.pone.0016617 10.7314/APJCP.2012.13.2.591 10.1186/1471-2407-12-83 10.1016/j.humpath.2009.11.014 10.1016/j.ygyno.2010.07.021 10.1007/s13277-011-0255-5 10.1158/1541-7786.MCR-11-0272 10.1100/tsw.2010.198 10.1002/hep.22256 10.1016/j.ccr.2006.01.025 10.1186/1756-9966-28-64 10.1016/j.bbrc.2008.09.089 10.1186/1471-2164-13-379 10.1007/s12032-010-9637-6 10.1016/j.canlet.2010.06.004 10.1097/PDM.0b013e3181efe2a9 10.2353/jmoldx.2010.090187 10.1371/journal.pone.0031862 10.1016/j.biocel.2009.02.021 10.3892/ol.2013.1251 10.1371/journal.pone.0002557 10.1007/s00109-007-0296-9 10.1016/j.devcel.2008.07.002 10.1007/s11010-013-1664-0 10.1016/j.lungcan.2010.07.014 10.1177/030089161209800618 10.1371/journal.pone.0024950 10.1136/gut.2008.175497 10.1038/nature10661 10.1016/j.bbrc.2008.12.098 10.1093/carcin/bgt333 10.1002/mc.21993 10.1002/ijc.25330 10.1016/j.humpath.2013.04.014 10.1002/gcc.20580 10.1371/journal.pone.0042978 10.1016/j.devcel.2008.07.008 10.1007/s11010-010-0582-7 10.1007/s10549-010-1303-3 10.1007/s00384-008-0455-7 10.1371/journal.pone.0029671 10.1002/gcc.20596 10.1016/S0960-9822(02)00809-6 10.1016/j.bbrc.2009.12.098 10.1038/sj.onc.1206529 10.1016/j.ejso.2010.10.010 10.1016/j.febslet.2011.03.039 10.1016/j.molonc.2012.04.001 10.1128/MCB.01652-07 10.1016/j.cbi.2013.09.003 10.1073/pnas.0808266105 10.1002/bjs.6628 10.1007/s10585-013-9569-6 10.1016/j.ejca.2009.04.039 10.1016/j.humpath.2007.09.001 10.1007/s13277-013-0974-x 10.1080/00313020701716425 10.1002/ajh.21667 |
| ContentType | Journal Article |
| Copyright | 2013 Elsevier Inc. Copyright © 2013 Elsevier Inc. All rights reserved. |
| Copyright_xml | – notice: 2013 Elsevier Inc. – notice: Copyright © 2013 Elsevier Inc. All rights reserved. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.yexmp.2013.12.004 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Chemistry |
| EISSN | 1096-0945 |
| EndPage | 107 |
| ExternalDocumentID | 24368110 10_1016_j_yexmp_2013_12_004 S0014480013001500 |
| Genre | Journal Article Review |
| GroupedDBID | --- --K --M -~X .55 .GJ .~1 0R~ 1B1 1RT 1~. 1~5 29G 3O- 4.4 457 4G. 53G 5GY 5VS 7-5 71M 8P~ 9JM AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AAXUO ABBQC ABFRF ABGSF ABJNI ABLVK ABMAC ABMZM ABUDA ABXDB ABYKQ ACDAQ ACGFO ACGFS ACRLP ADBBV ADEZE ADFGL ADMUD ADUVX AEBSH AEFWE AEHWI AEKER AENEX AFKWA AFTJW AFXIZ AGHFR AGRDE AGUBO AGYEJ AHHHB AHPSJ AIEXJ AIKHN AITUG AJBFU AJOXV AJRQY ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CAG COF CS3 DM4 DOVZS DU5 EBS EFBJH EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA GROUPED_DOAJ HDY HLW HMK HMO HVGLF HZ~ IHE J1W K-O KOM L7B LCYCR LG5 LX2 M29 M41 MO0 N9A O-L O9- OAUVE OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SAE SBG SDF SDG SDP SES SEW SPCBC SSH SSU SSZ T5K UHS UNMZH WUQ X7M XPP ZGI ZMT ZU3 ~G- AATTM AAXKI AAYWO AAYXX ABWVN ACIEU ACRPL ACVFH ADCNI ADNMO ADVLN AEIPS AEUPX AFJKZ AFPUW AGCQF AGQPQ AGRNS AIGII AIIUN AKBMS AKRWK AKYEP ANKPU APXCP CITATION CGR CUY CVF ECM EIF NPM 7X8 EFKBS |
| ID | FETCH-LOGICAL-c425t-4169ec644a1d910b1bf2755372f63d34aa6e9144068d30aa11684ec3e8d88383 |
| IEDL.DBID | .~1 |
| ISSN | 0014-4800 1096-0945 |
| IngestDate | Thu Sep 04 16:35:59 EDT 2025 Thu Apr 03 07:08:37 EDT 2025 Thu Apr 24 23:10:15 EDT 2025 Tue Jul 01 01:56:45 EDT 2025 Fri Feb 23 02:30:58 EST 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | miR-126 Carcinoma Cancer |
| Language | English |
| License | Copyright © 2013 Elsevier Inc. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c425t-4169ec644a1d910b1bf2755372f63d34aa6e9144068d30aa11684ec3e8d88383 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| PMID | 24368110 |
| PQID | 1511821752 |
| PQPubID | 23479 |
| PageCount | 10 |
| ParticipantIDs | proquest_miscellaneous_1511821752 pubmed_primary_24368110 crossref_primary_10_1016_j_yexmp_2013_12_004 crossref_citationtrail_10_1016_j_yexmp_2013_12_004 elsevier_sciencedirect_doi_10_1016_j_yexmp_2013_12_004 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | February 2014 2014-02-00 2014-Feb 20140201 |
| PublicationDateYYYYMMDD | 2014-02-01 |
| PublicationDate_xml | – month: 02 year: 2014 text: February 2014 |
| PublicationDecade | 2010 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | Experimental and molecular pathology |
| PublicationTitleAlternate | Exp Mol Pathol |
| PublicationYear | 2014 |
| Publisher | Elsevier Inc |
| Publisher_xml | – name: Elsevier Inc |
| References | Lam, Gopalan, Nassiri, Kasim, Dissanayake, Tang, Smith (bb0195) 2011; 5 Yang, Lan, Huang, Liu, Tong (bb0420) 2012; 7 Aslam, Taylor, Pringle, Jameson (bb0015) 2009; 96 Tavazoie, Alarcon, Oskarsson, Padua, Wang, Bos, Gerald, Massague (bb0350) 2008; 451 Bockmeyer, Christgen, Muller, Fischer, Ahrens, Langer, Kreipe, Lehmann (bb0025) 2011; 130 Wang, Tang, Le, Lu, Rader, Meyers, Zheng (bb0375) 2008; 3 Saito, Friedman, Chihara, Egger, Chuang, Liang (bb0295) 2009; 379 Feng, Chen, Yu, Su, Yu, Li, Cai, Yan, Liu, Zhu (bb0075) 2010; 298 Musiyenko, Bitko, Barik (bb0265) 2008; 86 Li, Zhang, Zhang, Ding, Wu, Fan (bb0215) 2010; 59 Slaby, Svoboda, Michalek, Vyzula (bb0330) 2009; 8 Lam, Ong, Ho (bb0190) 2008; 23 Li, Li, Wu, Li, Luo, Wang (bb0225) 2013; 381 White, Khella, Grigull, Adzovic, Youssef, Honey, Stewart, Pace, Bjarnason, Jewett, Evans, Gabril, Yousef (bb0405) 2011; 105 Hanke, Hoefig, Merz, Feller, Kausch, Jocham, Warnecke, Sczakiel (bb0115) 2010; 28 Salajegheh, Smith, Kasem, Gopalan, Nassiri, William, Lam (bb0305) 2011; 37 Sun, Bai, Zhang, Wang, Guo, Guo (bb0335) 2010; 391 Watahiki, Wang, Morris, Dennis, O'Dwyer, Gleave, Gout, Wang (bb0395) 2011; 6 El-Murr, Abidi, Wanherdrick, Svrcek, Gaub, Flejou, Hamelin, Duval, Lesuffleur (bb0065) 2012; 7 Gopalan, Pillai, Ebrahimi, Salajegheh, Lam, Le, Langsford, Ho, Smith, Lam (bb1000) 2014 Li, Lu, Sun, Mi, Zhang, Luo, Chen, Wang, Yan, Qian, Neilly, Jin, Zhang, Bohlander, Zhang, Larson, Le Beau, Thirman, Golub, Rowley, Chen (bb0230) 2008; 105 Liu, Qin, Zhao, Qi, Yao, Wang, Li, Wu (bb0245) 2013; 5 Fridman, Dotan, Barshack, David, Dov, Tabak, Zion, Benjamin, Benjamin, Kuker, Avivi, Rosenblatt, Polak-Charcon, Ramon, Rosenfeld, Spector (bb0085) 2010; 12 Hamada, Satoh, Fujibuchi, Hirota, Kanno, Unno, Masamune, Kikuta, Kume, Shimosegawa (bb0105) 2012; 10 Fish, Santoro, Morton, Yu, Yeh, Wythe, Ivey, Bruneau, Stainier, Srivastava (bb0080) 2008; 15 Wang, Shi, Wu, Xu, Wang, Zhang, Jiang, Gu (bb0390) 2012; 98 Diaz, Silva, Garcia, Lorenzo, Garcia, Pena, Rodriguez, Munoz, Garcia, Bonilla, Dominguez (bb0055) 2008; 47 Miko, Margitai, Czimmerer, Varkonyi, Dezso, Lanyi, Bacso, Scholtz (bb0255) 2011; 585 Tahiri, Leivonen, Luders, Steinfeld, Ragle Aure, Geisler, Makela, Nord, Riis, Yakhini, Kleivi Sahlberg, Borresen-Dale, Perala, Bukholm, Kristensen (bb0345) 2013; 35 Felli, Felicetti, Lustri, Errico, Bottero, Cannistraci, De Feo, Petrini, Pedini, Biffoni, Alvino, Negrini, Ferracin, Mattia, Care (bb0070) 2013; 8 Yu, Lo, Lam, Lang, Leung, Luk (bb0445) 2008; 144 Ahmed, Jeffries, Vos, Flake, Nuovo, Sinar, Naziri, Marcuard (bb0010) 2009; 6 Liu, Peng, Zheng, Wang, Qin (bb0235) 2009; 66 Zhu, Li, Long, Hui, Chen, Wang, Shen, Xu (bb0470) 2012; 44 Barshack, Meiri, Rosenwald, Lebanony, Bronfeld, Aviel-Ronen, Rosenblatt, Polak-Charcon, Leizerman, Ezagouri, Zepeniuk, Shabes, Cohen, Tabak, Cohen, Bentwich, Rosenfeld (bb0020) 2010; 42 Lam, Ong, Ho (bb0185) 2008; 39 Cammarata, Augugliaro, Salemi, Agueli, La Rosa, Dagnino, Civiletto, Messana, Marfia, Bica, Cascio, Floridia, Mineo, Russo, Fabbiano, Santoro (bb0035) 2010; 85 Chen, Miao, Fan, Han, Wu, Qiu, Tang, Peng (bb0040) 2013; 30 Lam, Ong, Giv, Ho (bb0180) 2008; 40 Li, Tang, Huang, Li, Li, Shen, Ma, Wang (bb0205) 2013; 380 Li, Li, Huang, Shen, Wang (bb0200) 2013; 38 Wang, Aurora, Johnson, Qi, McAnally, Hill, Richardson, Bassel-Duby, Olson (bb0370) 2008; 15 Han, Zhong, Teng, Fan, Tang, Wu, Chen, Wang, Qiu, Peng (bb0110) 2012; 6 Wang, Wu, Liu, Li, Li, Li, Shen (bb0385) 2010; 345 Powers, Alvarez, Kim, Monzon (bb0285) 2011; 20 Yu, Lo, Chan, Lam, Leung, Luk (bb0440) 2005; 11 Yanaihara, Caplen, Bowman, Seike, Kumamoto, Yi, Stephens, Okamoto, Yokota, Tanaka, Calin, Liu, Croce, Harris (bb0415) 2006; 9 Zhang, Du, Lin, Chen, Yang, Wang, Ma (bb0460) 2008; 377 Cho, Chow, Au (bb0045) 2009; 45 Lagos-Quintana, Rauhut, Yalcin, Meyer, Lendeckel, Tuschl (bb0175) 2002; 12 Shen, Hu, Uttarwar, Passegue, Largman (bb0325) 2008; 28 Otsubo, Akiyama, Hashimoto, Shimada, Goto, Yuasa (bb0270) 2011; 6 Wang, Du, Tian, Wu, Jiang, Zhang, Li, Wang, Wu, She, Liu, Fan, Meng (bb0380) 2011; 72 Guo, Sah, Beard, Willson, Markowitz, Guda (bb0095) 2008; 47 Ishihara, Sasaki, Tsuruda, Inokuchi, Nagai, Hasegawa, Yanagihara, Kamihira (bb0150) 2012; 36 Zhu, Zhang, Xie, Zhou, Chen, Hu, Bai, Shen, Yuan, Jing, Qin (bb0465) 2011; 351 Crawford, Brawner, Batte, Yu, Hunter, Otterson, Nuovo, Marsh, Nana-Sinkam (bb0050) 2008; 373 Kitano, Rahbari, Patterson, Xiong, Prasad, Wang, Zeiger, Kebebew (bb0165) 2011; 18 Meister, Schmidt (bb0250) 2010; 10 Khella, White, Faragalla, Gabril, Boazak, Dorian, Khalil, Antonios, Bao, Pasic, Honey, Stewart, Pace, Bjarnason, Jewett, Yousef (bb0160) 2012; 33 Huang, Chu (bb0140) 2013 Sasahira, Kurihara, Bhawal, Ueda, Shimomoto, Yamamoto, Kirita, Kuniyasu (bb0315) 2012; 107 Hu, Correa, Hoque, Guan, Ye, Huang, Swisher, Wu, Ajani, Xu (bb0135) 2011; 128 Miller, Chen, Gharib, Wang, Thomas, Misek, Giordano, Yee, Orringer, Hanash, Beer (bb0260) 2003; 22 Xu, Liu, Si, Ding (bb0410) 2013; 34 Saleh, Lam, Ho (bb0310) 2008; 40 Schmitt, Backes, Nourkami-Tutdibi, Leidinger, Deutscher, Beier, Gessler, Graf, Lenhof, Keller, Meese (bb0320) 2012; 13 Salajegheh, Pakneshan, Rahman, Dolan-Evans, Zhang, Kwong, Gopalan, Lo, Smith, Lam (bb0300) 2013; 44 Png, Halberg, Yoshida, Tavazoie (bb0280) 2012; 481 Gopalan, Smith, Nassiri, Yasuda, Salajegheh, Kim, Ho, Weinstein, Tang, Lam (bb0090) 2010; 41 Jiao, Frampton, Jacob, Pellegrino, Krell, Giamas, Tsim, Vlavianos, Cohen, Ahmad, Keller, Habib, Stebbing, Castellano (bb0155) 2012; 7 Li, Zhang, Luo, Ruan, Huang, Feng, Xiao, Zeng, Chen, Wu (bb0210) 2012; 28 Yu, Wang, Gong, Li, Yang, Cao, Wen, Wang, Yi (bb0435) 2009; 28 Donnem, Fenton, Lonvik, Berg, Eklo, Andersen, Stenvold, Al-Shibli, Al-Saad, Bremnes, Busund (bb0060) 2012; 7 Wang, Zheng, Guo, Ding (bb0360) 2010; 119 Hansen, Sorensen, Lindebjerg, Jakobsen (bb0120) 2012; 12 Agostini, Pucciarelli, Calore, Bedin, Enzo, Nitti (bb0005) 2010; 411 Wang, Chen, Li, Su, Yu, Cai, Li, Yu, Liu, Zhu (bb0365) 2013; 206 Ladeiro, Couchy, Balabaud, Bioulac-Sage, Pelletier, Rebouissou, Zucman-Rossi (bb0170) 2008; 47 Li, Wang, Zhang, Yi (bb0220) 2011; 28 Youssef, White, Grigull, Krizova, Samy, Mejia-Guerrero, Evans, Yousef (bb0430) 2011; 59 Resnick, Alder, Hagan, Richardson, Croce, Cohn (bb0290) 2009; 112 Weekes, Ho, Sebesan, Ong, Lam (bb0400) 2010; 25 Sun, Zhang, Bai, Guo (bb0340) 2010; 30 Hafez, Hassan, Zekri, Gaber, Al Rejaie, Sayed-Ahmed, Al Shabanah (bb0100) 2012; 13 Ishihara (10.1016/j.yexmp.2013.12.004_bb0150) 2012; 36 Wang (10.1016/j.yexmp.2013.12.004_bb0385) 2010; 345 Salajegheh (10.1016/j.yexmp.2013.12.004_bb0300) 2013; 44 Cammarata (10.1016/j.yexmp.2013.12.004_bb0035) 2010; 85 Zhu (10.1016/j.yexmp.2013.12.004_bb0470) 2012; 44 Miko (10.1016/j.yexmp.2013.12.004_bb0255) 2011; 585 Miller (10.1016/j.yexmp.2013.12.004_bb0260) 2003; 22 Guo (10.1016/j.yexmp.2013.12.004_bb0095) 2008; 47 Kitano (10.1016/j.yexmp.2013.12.004_bb0165) 2011; 18 Li (10.1016/j.yexmp.2013.12.004_bb0215) 2010; 59 Li (10.1016/j.yexmp.2013.12.004_bb0225) 2013; 381 Weekes (10.1016/j.yexmp.2013.12.004_bb0400) 2010; 25 Lam (10.1016/j.yexmp.2013.12.004_bb0195) 2011; 5 Khella (10.1016/j.yexmp.2013.12.004_bb0160) 2012; 33 Li (10.1016/j.yexmp.2013.12.004_bb0200) 2013; 38 Lagos-Quintana (10.1016/j.yexmp.2013.12.004_bb0175) 2002; 12 Tavazoie (10.1016/j.yexmp.2013.12.004_bb0350) 2008; 451 Fish (10.1016/j.yexmp.2013.12.004_bb0080) 2008; 15 Felli (10.1016/j.yexmp.2013.12.004_bb0070) 2013; 8 Gopalan (10.1016/j.yexmp.2013.12.004_bb1000) 2014 Li (10.1016/j.yexmp.2013.12.004_bb0205) 2013; 380 Musiyenko (10.1016/j.yexmp.2013.12.004_bb0265) 2008; 86 Watahiki (10.1016/j.yexmp.2013.12.004_bb0395) 2011; 6 Fridman (10.1016/j.yexmp.2013.12.004_bb0085) 2010; 12 Zhu (10.1016/j.yexmp.2013.12.004_bb0465) 2011; 351 Agostini (10.1016/j.yexmp.2013.12.004_bb0005) 2010; 411 Aslam (10.1016/j.yexmp.2013.12.004_bb0015) 2009; 96 Huang (10.1016/j.yexmp.2013.12.004_bb0140) 2013 Meister (10.1016/j.yexmp.2013.12.004_bb0250) 2010; 10 Powers (10.1016/j.yexmp.2013.12.004_bb0285) 2011; 20 Zhang (10.1016/j.yexmp.2013.12.004_bb0460) 2008; 377 Xu (10.1016/j.yexmp.2013.12.004_bb0410) 2013; 34 Cho (10.1016/j.yexmp.2013.12.004_bb0045) 2009; 45 Liu (10.1016/j.yexmp.2013.12.004_bb0235) 2009; 66 Hansen (10.1016/j.yexmp.2013.12.004_bb0120) 2012; 12 Otsubo (10.1016/j.yexmp.2013.12.004_bb0270) 2011; 6 Wang (10.1016/j.yexmp.2013.12.004_bb0370) 2008; 15 Li (10.1016/j.yexmp.2013.12.004_bb0230) 2008; 105 Li (10.1016/j.yexmp.2013.12.004_bb0220) 2011; 28 El-Murr (10.1016/j.yexmp.2013.12.004_bb0065) 2012; 7 Gopalan (10.1016/j.yexmp.2013.12.004_bb0090) 2010; 41 Lam (10.1016/j.yexmp.2013.12.004_bb0190) 2008; 23 Slaby (10.1016/j.yexmp.2013.12.004_bb0330) 2009; 8 Yanaihara (10.1016/j.yexmp.2013.12.004_bb0415) 2006; 9 Li (10.1016/j.yexmp.2013.12.004_bb0210) 2012; 28 Barshack (10.1016/j.yexmp.2013.12.004_bb0020) 2010; 42 Wang (10.1016/j.yexmp.2013.12.004_bb0365) 2013; 206 Resnick (10.1016/j.yexmp.2013.12.004_bb0290) 2009; 112 Ahmed (10.1016/j.yexmp.2013.12.004_bb0010) 2009; 6 Crawford (10.1016/j.yexmp.2013.12.004_bb0050) 2008; 373 Schmitt (10.1016/j.yexmp.2013.12.004_bb0320) 2012; 13 Hafez (10.1016/j.yexmp.2013.12.004_bb0100) 2012; 13 Bockmeyer (10.1016/j.yexmp.2013.12.004_bb0025) 2011; 130 Sun (10.1016/j.yexmp.2013.12.004_bb0340) 2010; 30 Tahiri (10.1016/j.yexmp.2013.12.004_bb0345) 2013; 35 Wang (10.1016/j.yexmp.2013.12.004_bb0375) 2008; 3 Sun (10.1016/j.yexmp.2013.12.004_bb0335) 2010; 391 Saito (10.1016/j.yexmp.2013.12.004_bb0295) 2009; 379 Salajegheh (10.1016/j.yexmp.2013.12.004_bb0305) 2011; 37 Wang (10.1016/j.yexmp.2013.12.004_bb0360) 2010; 119 Han (10.1016/j.yexmp.2013.12.004_bb0110) 2012; 6 Diaz (10.1016/j.yexmp.2013.12.004_bb0055) 2008; 47 Hamada (10.1016/j.yexmp.2013.12.004_bb0105) 2012; 10 Yu (10.1016/j.yexmp.2013.12.004_bb0445) 2008; 144 Png (10.1016/j.yexmp.2013.12.004_bb0280) 2012; 481 Donnem (10.1016/j.yexmp.2013.12.004_bb0060) 2012; 7 White (10.1016/j.yexmp.2013.12.004_bb0405) 2011; 105 Hu (10.1016/j.yexmp.2013.12.004_bb0135) 2011; 128 Youssef (10.1016/j.yexmp.2013.12.004_bb0430) 2011; 59 Shen (10.1016/j.yexmp.2013.12.004_bb0325) 2008; 28 Wang (10.1016/j.yexmp.2013.12.004_bb0390) 2012; 98 Lam (10.1016/j.yexmp.2013.12.004_bb0180) 2008; 40 Jiao (10.1016/j.yexmp.2013.12.004_bb0155) 2012; 7 Hanke (10.1016/j.yexmp.2013.12.004_bb0115) 2010; 28 Feng (10.1016/j.yexmp.2013.12.004_bb0075) 2010; 298 Liu (10.1016/j.yexmp.2013.12.004_bb0245) 2013; 5 Sasahira (10.1016/j.yexmp.2013.12.004_bb0315) 2012; 107 Yu (10.1016/j.yexmp.2013.12.004_bb0435) 2009; 28 Chen (10.1016/j.yexmp.2013.12.004_bb0040) 2013; 30 Yang (10.1016/j.yexmp.2013.12.004_bb0420) 2012; 7 Wang (10.1016/j.yexmp.2013.12.004_bb0380) 2011; 72 Ladeiro (10.1016/j.yexmp.2013.12.004_bb0170) 2008; 47 Saleh (10.1016/j.yexmp.2013.12.004_bb0310) 2008; 40 Yu (10.1016/j.yexmp.2013.12.004_bb0440) 2005; 11 Lam (10.1016/j.yexmp.2013.12.004_bb0185) 2008; 39 |
| References_xml | – volume: 37 start-page: 93 year: 2011 end-page: 99 ident: bb0305 article-title: Single nucleotide polymorphisms and mRNA expression of VEGF-A in papillary thyroid carcinoma: potential markers for aggressive phenotypes publication-title: Eur. J. Surg. Oncol. – volume: 47 start-page: 939 year: 2008 end-page: 946 ident: bb0095 article-title: The noncoding RNA, miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon cancers publication-title: Genes Chromosomes Cancer – volume: 345 start-page: 283 year: 2010 end-page: 290 ident: bb0385 article-title: Differential miRNA expression and their target genes between NGX6-positive and negative colon cancer cells publication-title: Mol. Cell. Biochem. – volume: 119 start-page: 586 year: 2010 end-page: 593 ident: bb0360 article-title: Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor publication-title: Gynecol. Oncol. – volume: 39 start-page: 599 year: 2008 end-page: 604 ident: bb0185 article-title: Aurora kinase expression in colorectal adenocarcinoma: correlations with clinicopathological features, p16 expression, and telomerase activity publication-title: Hum. Pathol. – volume: 12 start-page: 735 year: 2002 end-page: 739 ident: bb0175 article-title: Identification of tissue-specific microRNAs from mouse publication-title: Curr. Biol. – volume: 206 start-page: 230 year: 2013 end-page: 238 ident: bb0365 article-title: CRKL promotes cell proliferation in gastric cancer and is negatively regulated by miR-126 publication-title: Chem. Biol. Interact. – volume: 10 start-page: 3 year: 2012 end-page: 10 ident: bb0105 article-title: MiR-126 acts as a tumor suppressor in pancreatic cancer cells via the regulation of ADAM9 publication-title: Mol. Cancer Res. – volume: 23 start-page: 587 year: 2008 end-page: 594 ident: bb0190 article-title: hTERT expression in colorectal adenocarcinoma: correlations with p21, p53 expressions and clinicopathological features publication-title: Int. J. Colorectal Dis. – volume: 44 start-page: 2204 year: 2013 end-page: 2212 ident: bb0300 article-title: Co-regulatory potential of vascular endothelial growth factor-A and vascular endothelial growth factor-C in thyroid carcinoma publication-title: Hum. Pathol. – volume: 391 start-page: 1483 year: 2010 end-page: 1489 ident: bb0335 article-title: miR-126 inhibits non-small cell lung cancer cells proliferation by targeting EGFL7 publication-title: Biochem. Biophys. Res. Commun. – volume: 33 start-page: 131 year: 2012 end-page: 140 ident: bb0160 article-title: Exploring the role of miRNAs in renal cell carcinoma progression and metastasis through bioinformatic and experimental analyses publication-title: Tumour Biol. – volume: 6 start-page: 281 year: 2009 end-page: 295 ident: bb0010 article-title: Diagnostic microRNA markers for screening sporadic human colon cancer and active ulcerative colitis in stool and tissue publication-title: Cancer Genomics Proteomics – volume: 40 start-page: 25 year: 2008 end-page: 30 ident: bb0310 article-title: Real-time PCR quantification of human telomerase reverse transcriptase (hTERT) in colorectal cancer publication-title: Pathology – volume: 7 start-page: e31862 year: 2012 ident: bb0065 article-title: MiRNA genes constitute new targets for microsatellite instability in colorectal cancer publication-title: PLoS One – volume: 7 start-page: e29671 year: 2012 ident: bb0060 article-title: MicroRNA signatures in tumor tissue related to angiogenesis in non-small cell lung cancer publication-title: PLoS One – volume: 59 start-page: 579 year: 2010 end-page: 585 ident: bb0215 article-title: Survival prediction of gastric cancer by a seven-microRNA signature publication-title: Gut – volume: 34 start-page: 3871 year: 2013 end-page: 3877 ident: bb0410 article-title: MicroRNA-126 inhibits osteosarcoma cells proliferation by targeting Sirt1 publication-title: Tumour Biol. – volume: 8 start-page: e56824 year: 2013 ident: bb0070 article-title: miR-126&126* restored expressions play a tumor suppressor role by directly regulating ADAM9 and MMP7 in melanoma publication-title: PLoS One – volume: 85 start-page: 331 year: 2010 end-page: 339 ident: bb0035 article-title: Differential expression of specific microRNA and their targets in acute myeloid leukemia publication-title: Am. J. Hematol. – volume: 12 start-page: 687 year: 2010 end-page: 696 ident: bb0085 article-title: Accurate molecular classification of renal tumors using microRNA expression publication-title: J. Mol. Diagn. – volume: 451 start-page: 147 year: 2008 end-page: 152 ident: bb0350 article-title: Endogenous human microRNAs that suppress breast cancer metastasis publication-title: Nature – volume: 25 start-page: 907 year: 2010 ident: bb0400 article-title: Irinotecan and colorectal cancer: the role of p53, VEGF-C and alpha-B-crystallin expression publication-title: Int. J. Colorectal Dis. – volume: 40 start-page: 580 year: 2008 end-page: 585 ident: bb0180 article-title: p16 expression in colorectal adenocarcinoma: marker of aggressiveness and morphological types publication-title: Pathology – volume: 18 start-page: 3443 year: 2011 end-page: 3452 ident: bb0165 article-title: Expression profiling of difficult-to-diagnose thyroid histologic subtypes shows distinct expression profiles and identify candidate diagnostic microRNAs publication-title: Ann. Surg. Oncol. – volume: 45 start-page: 2197 year: 2009 end-page: 2206 ident: bb0045 article-title: Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation publication-title: Eur. J. Cancer – volume: 28 start-page: 655 year: 2010 end-page: 661 ident: bb0115 article-title: A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer publication-title: Urol. Oncol. – year: 2013 ident: bb0140 article-title: Repression of miR-126 and upregulation of adrenomedullin in the stromal endothelium by cancer-stromal cross talks confers angiogenesis of cervical cancer publication-title: Oncogene – volume: 351 start-page: 157 year: 2011 end-page: 164 ident: bb0465 article-title: Endothelial-specific intron-derived miR-126 is down-regulated in human breast cancer and targets both VEGFA and PIK3R2 publication-title: Mol. Cell. Biochem. – volume: 381 start-page: 233 year: 2013 end-page: 242 ident: bb0225 article-title: Expression of miR-126 suppresses migration and invasion of colon cancer cells by targeting CXCR4 publication-title: Mol. Cell. Biochem. – volume: 13 start-page: 379 year: 2012 ident: bb0320 article-title: Treatment-independent miRNA signature in blood of Wilms tumor patients publication-title: BMC Genomics – volume: 6 start-page: 445 year: 2012 end-page: 457 ident: bb0110 article-title: Identification of recurrence-related microRNAs in hepatocellular carcinoma following liver transplantation publication-title: Mol. Oncol. – volume: 380 start-page: 107 year: 2013 end-page: 119 ident: bb0205 article-title: MiR-126 suppresses colon cancer cell proliferation and invasion via inhibiting RhoA/ROCK signaling pathway publication-title: Mol. Cell. Biochem. – volume: 42 start-page: 1355 year: 2010 end-page: 1362 ident: bb0020 article-title: Differential diagnosis of hepatocellular carcinoma from metastatic tumors in the liver using microRNA expression publication-title: Int. J. Biochem. Cell Biol. – volume: 411 start-page: 1181 year: 2010 end-page: 1186 ident: bb0005 article-title: miRNAs in colon and rectal cancer: a consensus for their true clinical value publication-title: Clin. Chim. Acta – volume: 15 start-page: 272 year: 2008 end-page: 284 ident: bb0080 article-title: miR-126 regulates angiogenic signaling and vascular integrity publication-title: Dev. Cell – volume: 28 start-page: 64 year: 2009 ident: bb0435 article-title: The expression profile of microRNAs in a model of 7,12-dimethyl-benz[a]anthrance-induced oral carcinogenesis in Syrian hamster publication-title: J. Exp. Clin. Cancer Res. – volume: 9 start-page: 189 year: 2006 end-page: 198 ident: bb0415 article-title: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis publication-title: Cancer Cell – volume: 6 start-page: e24950 year: 2011 ident: bb0395 article-title: MicroRNAs associated with metastatic prostate cancer publication-title: PLoS One – volume: 377 start-page: 136 year: 2008 end-page: 140 ident: bb0460 article-title: The cell growth suppressor, mir-126, targets IRS-1 publication-title: Biochem. Biophys. Res. Commun. – volume: 28 start-page: 1054 year: 2011 end-page: 1057 ident: bb0220 article-title: Down-regulation of miR-126 expression in colorectal cancer and its clinical significance publication-title: Med. Oncol. – volume: 128 start-page: 132 year: 2011 end-page: 143 ident: bb0135 article-title: Prognostic significance of differentially expressed miRNAs in esophageal cancer publication-title: Int. J. Cancer – volume: 379 start-page: 726 year: 2009 end-page: 731 ident: bb0295 article-title: Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cells publication-title: Biochem. Biophys. Res. Commun. – volume: 38 start-page: 809 year: 2013 end-page: 817 ident: bb0200 article-title: miR-126 inhibits colon cancer proliferation and invasion through targeting IRS1, SLC7A5 and TOM1 gene publication-title: Zhong Nan Da Xue Xue Bao Yi Xue Ban – volume: 22 start-page: 7950 year: 2003 end-page: 7957 ident: bb0260 article-title: Increased C-CRK proto-oncogene expression is associated with an aggressive phenotype in lung adenocarcinomas publication-title: Oncogene – volume: 107 start-page: 700 year: 2012 end-page: 706 ident: bb0315 article-title: Downregulation of miR-126 induces angiogenesis and lymphangiogenesis by activation of VEGF-A in oral cancer publication-title: Br. J. Cancer – volume: 44 start-page: 519 year: 2012 end-page: 526 ident: bb0470 article-title: miR-126 enhances the sensitivity of non-small cell lung cancer cells to anticancer agents by targeting vascular endothelial growth factor A publication-title: Acta Biochim. Biophys. Sin. (Shanghai) – volume: 35 start-page: 76 year: 2013 end-page: 85 ident: bb0345 article-title: Deregulation of cancer-related miRNAs is a common event in both benign and malignant human breast tumors publication-title: Carcinogenesis – volume: 96 start-page: 702 year: 2009 end-page: 710 ident: bb0015 article-title: MicroRNAs are novel biomarkers of colorectal cancer publication-title: Br. J. Surg. – volume: 13 start-page: 591 year: 2012 end-page: 598 ident: bb0100 article-title: MicroRNAs and metastasis-related gene expression in Egyptian breast cancer patients publication-title: Asian Pac. J. Cancer Prev. – volume: 8 start-page: 102 year: 2009 ident: bb0330 article-title: MicroRNAs in colorectal cancer: translation of molecular biology into clinical application publication-title: Mol. Cancer – volume: 112 start-page: 55 year: 2009 end-page: 59 ident: bb0290 article-title: The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform publication-title: Gynecol. Oncol. – volume: 30 start-page: 651 year: 2013 end-page: 658 ident: bb0040 article-title: Decreased expression of miR-126 correlates with metastatic recurrence of hepatocellular carcinoma publication-title: Clin. Exp. Metastasis – volume: 7 start-page: e32068 year: 2012 ident: bb0155 article-title: MicroRNAs targeting oncogenes are down-regulated in pancreatic malignant transformation from benign tumors publication-title: PLoS One – volume: 86 start-page: 313 year: 2008 end-page: 322 ident: bb0265 article-title: Ectopic expression of miR-126*, an intronic product of the vascular endothelial EGF-like 7 gene, regulates protein translation and invasiveness of prostate cancer LNCaP cells publication-title: J. Mol. Med. (Berl) – volume: 105 start-page: 1741 year: 2011 end-page: 1749 ident: bb0405 article-title: miRNA profiling in metastatic renal cell carcinoma reveals a tumour-suppressor effect for miR-215 publication-title: Br. J. Cancer – volume: 5 start-page: 1639 year: 2013 end-page: 1642 ident: bb0245 article-title: Differential expression of miRNAs in esophageal cancer tissue publication-title: Oncol. Lett. – volume: 59 start-page: 721 year: 2011 end-page: 730 ident: bb0430 article-title: Accurate molecular classification of kidney cancer subtypes using microRNA signature publication-title: Eur. Urol. – volume: 36 start-page: 560 year: 2012 end-page: 565 ident: bb0150 article-title: Impact of miR-155 and miR-126 as novel biomarkers on the assessment of disease progression and prognosis in adult T-cell leukemia publication-title: Cancer Epidemiol. – volume: 30 start-page: 767 year: 2010 end-page: 770 ident: bb0340 article-title: miR-126 modulates the expression of epidermal growth factor-like domain 7 in human umbilical vein endothelial cells in vitro publication-title: Nan Fang Yi Ke Da Xue Xue Bao – volume: 10 start-page: 2090 year: 2010 end-page: 2100 ident: bb0250 article-title: miR-126 and miR-126*: new players in cancer publication-title: ScientificWorldJournal – volume: 41 start-page: 1009 year: 2010 end-page: 1015 ident: bb0090 article-title: GAEC1 and colorectal cancer: a study of the relationships between a novel oncogene and clinicopathologic features publication-title: Hum. Pathol. – volume: 6 start-page: e16617 year: 2011 ident: bb0270 article-title: MicroRNA-126 inhibits SOX2 expression and contributes to gastric carcinogenesis publication-title: PLoS One – volume: 28 start-page: 4609 year: 2008 end-page: 4619 ident: bb0325 article-title: MicroRNA-126 regulates HOXA9 by binding to the homeobox publication-title: Mol. Cell. Biol. – volume: 481 start-page: 190 year: 2012 end-page: 194 ident: bb0280 article-title: A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells publication-title: Nature – volume: 15 start-page: 261 year: 2008 end-page: 271 ident: bb0370 article-title: The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis publication-title: Dev. Cell – volume: 11 start-page: 8063 year: 2005 end-page: 8069 ident: bb0440 article-title: Increased expression of vascular endothelial growth factor C in papillary thyroid carcinoma correlates with cervical lymph node metastases publication-title: Clin. Cancer Res. – volume: 12 start-page: 83 year: 2012 ident: bb0120 article-title: The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer publication-title: BMC Cancer – volume: 47 start-page: 1955 year: 2008 end-page: 1963 ident: bb0170 article-title: MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations publication-title: Hepatology – volume: 373 start-page: 607 year: 2008 end-page: 612 ident: bb0050 article-title: MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines publication-title: Biochem. Biophys. Res. Commun. – volume: 98 start-page: 792 year: 2012 end-page: 799 ident: bb0390 article-title: Use of Luminex xMAP bead-based suspension array for detecting microRNA in NSCLC tissues and its clinical application publication-title: Tumori – volume: 47 start-page: 794 year: 2008 end-page: 802 ident: bb0055 article-title: Deregulated expression of miR-106a predicts survival in human colon cancer patients publication-title: Genes Chromosomes Cancer – volume: 20 start-page: 63 year: 2011 end-page: 70 ident: bb0285 article-title: Molecular classification of adult renal epithelial neoplasms using microRNA expression and virtual karyotyping publication-title: Diagn. Mol. Pathol. – volume: 144 start-page: 934 year: 2008 end-page: 940 ident: bb0445 article-title: The potential clinical relevance of serum vascular endothelial growth factor (VEGF) and VEGF-C in recurrent papillary thyroid carcinoma publication-title: Surgery – volume: 298 start-page: 50 year: 2010 end-page: 63 ident: bb0075 article-title: miR-126 functions as a tumour suppressor in human gastric cancer publication-title: Cancer Lett. – volume: 3 start-page: e2557 year: 2008 ident: bb0375 article-title: Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth publication-title: PLoS One – volume: 585 start-page: 1191 year: 2011 end-page: 1196 ident: bb0255 article-title: miR-126 inhibits proliferation of small cell lung cancer cells by targeting SLC7A5 publication-title: FEBS Lett. – volume: 5 start-page: 475 year: 2011 end-page: 481 ident: bb0195 article-title: Altered JS-2 expression in colorectal cancers and its clinical pathological relevance publication-title: Mol Oncol. – volume: 72 start-page: 92 year: 2011 end-page: 99 ident: bb0380 article-title: Expression and function of miRNA in postoperative radiotherapy sensitive and resistant patients of non-small cell lung cancer publication-title: Lung Cancer – volume: 28 start-page: 77 year: 2012 end-page: 84 ident: bb0210 article-title: Identification of aberrantly expressed miRNAs in rectal cancer publication-title: Oncol. Rep. – volume: 7 start-page: e42978 year: 2012 ident: bb0420 article-title: MicroRNA-126 inhibits tumor cell growth and its expression level correlates with poor survival in non-small cell lung cancer patients publication-title: PLoS One – volume: 130 start-page: 735 year: 2011 end-page: 745 ident: bb0025 article-title: MicroRNA profiles of healthy basal and luminal mammary epithelial cells are distinct and reflected in different breast cancer subtypes publication-title: Breast Cancer Res. Treat. – year: 2014 ident: bb1000 article-title: Regulation of microRNA-1288 in colorectal cancer: Altered expression and its clinicopathological significance publication-title: Mol Carcinog. – volume: 66 start-page: 169 year: 2009 end-page: 175 ident: bb0235 article-title: MiR-126 restoration down-regulate VEGF and inhibit the growth of lung cancer cell lines in vitro and in vivo publication-title: Lung Cancer – volume: 105 start-page: 15535 year: 2008 end-page: 15540 ident: bb0230 article-title: Distinct microRNA expression profiles in acute myeloid leukemia with common translocations publication-title: Proc. Natl. Acad. Sci. U. S. A. – volume: 28 start-page: 655 year: 2010 ident: 10.1016/j.yexmp.2013.12.004_bb0115 article-title: A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer publication-title: Urol. Oncol. doi: 10.1016/j.urolonc.2009.01.027 – volume: 8 start-page: 102 year: 2009 ident: 10.1016/j.yexmp.2013.12.004_bb0330 article-title: MicroRNAs in colorectal cancer: translation of molecular biology into clinical application publication-title: Mol. Cancer doi: 10.1186/1476-4598-8-102 – volume: 373 start-page: 607 year: 2008 ident: 10.1016/j.yexmp.2013.12.004_bb0050 article-title: MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines publication-title: Biochem. Biophys. Res. Commun. doi: 10.1016/j.bbrc.2008.06.090 – volume: 40 start-page: 580 issue: 6 year: 2008 ident: 10.1016/j.yexmp.2013.12.004_bb0180 article-title: p16 expression in colorectal adenocarcinoma: marker of aggressiveness and morphological types publication-title: Pathology doi: 10.1080/00313020802320713 – volume: 411 start-page: 1181 year: 2010 ident: 10.1016/j.yexmp.2013.12.004_bb0005 article-title: miRNAs in colon and rectal cancer: a consensus for their true clinical value publication-title: Clin. Chim. Acta doi: 10.1016/j.cca.2010.05.002 – volume: 8 start-page: e56824 year: 2013 ident: 10.1016/j.yexmp.2013.12.004_bb0070 article-title: miR-126&126* restored expressions play a tumor suppressor role by directly regulating ADAM9 and MMP7 in melanoma publication-title: PLoS One doi: 10.1371/journal.pone.0056824 – volume: 351 start-page: 157 year: 2011 ident: 10.1016/j.yexmp.2013.12.004_bb0465 article-title: Endothelial-specific intron-derived miR-126 is down-regulated in human breast cancer and targets both VEGFA and PIK3R2 publication-title: Mol. Cell. Biochem. doi: 10.1007/s11010-011-0723-7 – volume: 38 start-page: 809 year: 2013 ident: 10.1016/j.yexmp.2013.12.004_bb0200 article-title: miR-126 inhibits colon cancer proliferation and invasion through targeting IRS1, SLC7A5 and TOM1 gene publication-title: Zhong Nan Da Xue Xue Bao Yi Xue Ban – volume: 381 start-page: 233 year: 2013 ident: 10.1016/j.yexmp.2013.12.004_bb0225 article-title: Expression of miR-126 suppresses migration and invasion of colon cancer cells by targeting CXCR4 publication-title: Mol. Cell. Biochem. doi: 10.1007/s11010-013-1707-6 – volume: 5 start-page: 475 year: 2011 ident: 10.1016/j.yexmp.2013.12.004_bb0195 article-title: Altered JS-2 expression in colorectal cancers and its clinical pathological relevance publication-title: Mol Oncol. doi: 10.1016/j.molonc.2011.06.003 – volume: 25 start-page: 907 year: 2010 ident: 10.1016/j.yexmp.2013.12.004_bb0400 article-title: Irinotecan and colorectal cancer: the role of p53, VEGF-C and alpha-B-crystallin expression publication-title: Int. J. Colorectal Dis. doi: 10.1007/s00384-009-0862-4 – volume: 105 start-page: 1741 year: 2011 ident: 10.1016/j.yexmp.2013.12.004_bb0405 article-title: miRNA profiling in metastatic renal cell carcinoma reveals a tumour-suppressor effect for miR-215 publication-title: Br. J. Cancer doi: 10.1038/bjc.2011.401 – volume: 44 start-page: 519 year: 2012 ident: 10.1016/j.yexmp.2013.12.004_bb0470 article-title: miR-126 enhances the sensitivity of non-small cell lung cancer cells to anticancer agents by targeting vascular endothelial growth factor A publication-title: Acta Biochim. Biophys. Sin. (Shanghai) doi: 10.1093/abbs/gms026 – volume: 451 start-page: 147 year: 2008 ident: 10.1016/j.yexmp.2013.12.004_bb0350 article-title: Endogenous human microRNAs that suppress breast cancer metastasis publication-title: Nature doi: 10.1038/nature06487 – volume: 112 start-page: 55 year: 2009 ident: 10.1016/j.yexmp.2013.12.004_bb0290 article-title: The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform publication-title: Gynecol. Oncol. doi: 10.1016/j.ygyno.2008.08.036 – volume: 7 start-page: e32068 year: 2012 ident: 10.1016/j.yexmp.2013.12.004_bb0155 article-title: MicroRNAs targeting oncogenes are down-regulated in pancreatic malignant transformation from benign tumors publication-title: PLoS One doi: 10.1371/journal.pone.0032068 – volume: 66 start-page: 169 year: 2009 ident: 10.1016/j.yexmp.2013.12.004_bb0235 article-title: MiR-126 restoration down-regulate VEGF and inhibit the growth of lung cancer cell lines in vitro and in vivo publication-title: Lung Cancer doi: 10.1016/j.lungcan.2009.01.010 – volume: 36 start-page: 560 year: 2012 ident: 10.1016/j.yexmp.2013.12.004_bb0150 article-title: Impact of miR-155 and miR-126 as novel biomarkers on the assessment of disease progression and prognosis in adult T-cell leukemia publication-title: Cancer Epidemiol. doi: 10.1016/j.canep.2012.07.002 – volume: 18 start-page: 3443 year: 2011 ident: 10.1016/j.yexmp.2013.12.004_bb0165 article-title: Expression profiling of difficult-to-diagnose thyroid histologic subtypes shows distinct expression profiles and identify candidate diagnostic microRNAs publication-title: Ann. Surg. Oncol. doi: 10.1245/s10434-011-1766-4 – volume: 107 start-page: 700 year: 2012 ident: 10.1016/j.yexmp.2013.12.004_bb0315 article-title: Downregulation of miR-126 induces angiogenesis and lymphangiogenesis by activation of VEGF-A in oral cancer publication-title: Br. J. Cancer doi: 10.1038/bjc.2012.330 – volume: 144 start-page: 934 year: 2008 ident: 10.1016/j.yexmp.2013.12.004_bb0445 article-title: The potential clinical relevance of serum vascular endothelial growth factor (VEGF) and VEGF-C in recurrent papillary thyroid carcinoma publication-title: Surgery doi: 10.1016/j.surg.2008.07.027 – volume: 11 start-page: 8063 year: 2005 ident: 10.1016/j.yexmp.2013.12.004_bb0440 article-title: Increased expression of vascular endothelial growth factor C in papillary thyroid carcinoma correlates with cervical lymph node metastases publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-05-0646 – year: 2013 ident: 10.1016/j.yexmp.2013.12.004_bb0140 article-title: Repression of miR-126 and upregulation of adrenomedullin in the stromal endothelium by cancer-stromal cross talks confers angiogenesis of cervical cancer publication-title: Oncogene doi: 10.1038/onc.2013.335 – volume: 59 start-page: 721 year: 2011 ident: 10.1016/j.yexmp.2013.12.004_bb0430 article-title: Accurate molecular classification of kidney cancer subtypes using microRNA signature publication-title: Eur. Urol. doi: 10.1016/j.eururo.2011.01.004 – volume: 6 start-page: e16617 year: 2011 ident: 10.1016/j.yexmp.2013.12.004_bb0270 article-title: MicroRNA-126 inhibits SOX2 expression and contributes to gastric carcinogenesis publication-title: PLoS One doi: 10.1371/journal.pone.0016617 – volume: 13 start-page: 591 year: 2012 ident: 10.1016/j.yexmp.2013.12.004_bb0100 article-title: MicroRNAs and metastasis-related gene expression in Egyptian breast cancer patients publication-title: Asian Pac. J. Cancer Prev. doi: 10.7314/APJCP.2012.13.2.591 – volume: 12 start-page: 83 year: 2012 ident: 10.1016/j.yexmp.2013.12.004_bb0120 article-title: The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer publication-title: BMC Cancer doi: 10.1186/1471-2407-12-83 – volume: 41 start-page: 1009 issue: 7 year: 2010 ident: 10.1016/j.yexmp.2013.12.004_bb0090 article-title: GAEC1 and colorectal cancer: a study of the relationships between a novel oncogene and clinicopathologic features publication-title: Hum. Pathol. doi: 10.1016/j.humpath.2009.11.014 – volume: 119 start-page: 586 year: 2010 ident: 10.1016/j.yexmp.2013.12.004_bb0360 article-title: Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor publication-title: Gynecol. Oncol. doi: 10.1016/j.ygyno.2010.07.021 – volume: 33 start-page: 131 year: 2012 ident: 10.1016/j.yexmp.2013.12.004_bb0160 article-title: Exploring the role of miRNAs in renal cell carcinoma progression and metastasis through bioinformatic and experimental analyses publication-title: Tumour Biol. doi: 10.1007/s13277-011-0255-5 – volume: 10 start-page: 3 year: 2012 ident: 10.1016/j.yexmp.2013.12.004_bb0105 article-title: MiR-126 acts as a tumor suppressor in pancreatic cancer cells via the regulation of ADAM9 publication-title: Mol. Cancer Res. doi: 10.1158/1541-7786.MCR-11-0272 – volume: 10 start-page: 2090 year: 2010 ident: 10.1016/j.yexmp.2013.12.004_bb0250 article-title: miR-126 and miR-126*: new players in cancer publication-title: ScientificWorldJournal doi: 10.1100/tsw.2010.198 – volume: 47 start-page: 1955 year: 2008 ident: 10.1016/j.yexmp.2013.12.004_bb0170 article-title: MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations publication-title: Hepatology doi: 10.1002/hep.22256 – volume: 9 start-page: 189 year: 2006 ident: 10.1016/j.yexmp.2013.12.004_bb0415 article-title: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis publication-title: Cancer Cell doi: 10.1016/j.ccr.2006.01.025 – volume: 28 start-page: 64 year: 2009 ident: 10.1016/j.yexmp.2013.12.004_bb0435 article-title: The expression profile of microRNAs in a model of 7,12-dimethyl-benz[a]anthrance-induced oral carcinogenesis in Syrian hamster publication-title: J. Exp. Clin. Cancer Res. doi: 10.1186/1756-9966-28-64 – volume: 377 start-page: 136 year: 2008 ident: 10.1016/j.yexmp.2013.12.004_bb0460 article-title: The cell growth suppressor, mir-126, targets IRS-1 publication-title: Biochem. Biophys. Res. Commun. doi: 10.1016/j.bbrc.2008.09.089 – volume: 13 start-page: 379 year: 2012 ident: 10.1016/j.yexmp.2013.12.004_bb0320 article-title: Treatment-independent miRNA signature in blood of Wilms tumor patients publication-title: BMC Genomics doi: 10.1186/1471-2164-13-379 – volume: 28 start-page: 1054 year: 2011 ident: 10.1016/j.yexmp.2013.12.004_bb0220 article-title: Down-regulation of miR-126 expression in colorectal cancer and its clinical significance publication-title: Med. Oncol. doi: 10.1007/s12032-010-9637-6 – volume: 298 start-page: 50 year: 2010 ident: 10.1016/j.yexmp.2013.12.004_bb0075 article-title: miR-126 functions as a tumour suppressor in human gastric cancer publication-title: Cancer Lett. doi: 10.1016/j.canlet.2010.06.004 – volume: 20 start-page: 63 year: 2011 ident: 10.1016/j.yexmp.2013.12.004_bb0285 article-title: Molecular classification of adult renal epithelial neoplasms using microRNA expression and virtual karyotyping publication-title: Diagn. Mol. Pathol. doi: 10.1097/PDM.0b013e3181efe2a9 – volume: 12 start-page: 687 year: 2010 ident: 10.1016/j.yexmp.2013.12.004_bb0085 article-title: Accurate molecular classification of renal tumors using microRNA expression publication-title: J. Mol. Diagn. doi: 10.2353/jmoldx.2010.090187 – volume: 7 start-page: e31862 year: 2012 ident: 10.1016/j.yexmp.2013.12.004_bb0065 article-title: MiRNA genes constitute new targets for microsatellite instability in colorectal cancer publication-title: PLoS One doi: 10.1371/journal.pone.0031862 – volume: 28 start-page: 77 year: 2012 ident: 10.1016/j.yexmp.2013.12.004_bb0210 article-title: Identification of aberrantly expressed miRNAs in rectal cancer publication-title: Oncol. Rep. – volume: 42 start-page: 1355 year: 2010 ident: 10.1016/j.yexmp.2013.12.004_bb0020 article-title: Differential diagnosis of hepatocellular carcinoma from metastatic tumors in the liver using microRNA expression publication-title: Int. J. Biochem. Cell Biol. doi: 10.1016/j.biocel.2009.02.021 – volume: 5 start-page: 1639 year: 2013 ident: 10.1016/j.yexmp.2013.12.004_bb0245 article-title: Differential expression of miRNAs in esophageal cancer tissue publication-title: Oncol. Lett. doi: 10.3892/ol.2013.1251 – volume: 3 start-page: e2557 year: 2008 ident: 10.1016/j.yexmp.2013.12.004_bb0375 article-title: Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth publication-title: PLoS One doi: 10.1371/journal.pone.0002557 – volume: 86 start-page: 313 year: 2008 ident: 10.1016/j.yexmp.2013.12.004_bb0265 article-title: Ectopic expression of miR-126*, an intronic product of the vascular endothelial EGF-like 7 gene, regulates protein translation and invasiveness of prostate cancer LNCaP cells publication-title: J. Mol. Med. (Berl) doi: 10.1007/s00109-007-0296-9 – volume: 15 start-page: 261 year: 2008 ident: 10.1016/j.yexmp.2013.12.004_bb0370 article-title: The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis publication-title: Dev. Cell doi: 10.1016/j.devcel.2008.07.002 – volume: 380 start-page: 107 year: 2013 ident: 10.1016/j.yexmp.2013.12.004_bb0205 article-title: MiR-126 suppresses colon cancer cell proliferation and invasion via inhibiting RhoA/ROCK signaling pathway publication-title: Mol. Cell. Biochem. doi: 10.1007/s11010-013-1664-0 – volume: 30 start-page: 767 year: 2010 ident: 10.1016/j.yexmp.2013.12.004_bb0340 article-title: miR-126 modulates the expression of epidermal growth factor-like domain 7 in human umbilical vein endothelial cells in vitro publication-title: Nan Fang Yi Ke Da Xue Xue Bao – volume: 72 start-page: 92 year: 2011 ident: 10.1016/j.yexmp.2013.12.004_bb0380 article-title: Expression and function of miRNA in postoperative radiotherapy sensitive and resistant patients of non-small cell lung cancer publication-title: Lung Cancer doi: 10.1016/j.lungcan.2010.07.014 – volume: 6 start-page: 281 year: 2009 ident: 10.1016/j.yexmp.2013.12.004_bb0010 article-title: Diagnostic microRNA markers for screening sporadic human colon cancer and active ulcerative colitis in stool and tissue publication-title: Cancer Genomics Proteomics – volume: 98 start-page: 792 year: 2012 ident: 10.1016/j.yexmp.2013.12.004_bb0390 article-title: Use of Luminex xMAP bead-based suspension array for detecting microRNA in NSCLC tissues and its clinical application publication-title: Tumori doi: 10.1177/030089161209800618 – volume: 6 start-page: e24950 year: 2011 ident: 10.1016/j.yexmp.2013.12.004_bb0395 article-title: MicroRNAs associated with metastatic prostate cancer publication-title: PLoS One doi: 10.1371/journal.pone.0024950 – volume: 59 start-page: 579 year: 2010 ident: 10.1016/j.yexmp.2013.12.004_bb0215 article-title: Survival prediction of gastric cancer by a seven-microRNA signature publication-title: Gut doi: 10.1136/gut.2008.175497 – volume: 481 start-page: 190 year: 2012 ident: 10.1016/j.yexmp.2013.12.004_bb0280 article-title: A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells publication-title: Nature doi: 10.1038/nature10661 – volume: 379 start-page: 726 year: 2009 ident: 10.1016/j.yexmp.2013.12.004_bb0295 article-title: Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cells publication-title: Biochem. Biophys. Res. Commun. doi: 10.1016/j.bbrc.2008.12.098 – volume: 35 start-page: 76 year: 2013 ident: 10.1016/j.yexmp.2013.12.004_bb0345 article-title: Deregulation of cancer-related miRNAs is a common event in both benign and malignant human breast tumors publication-title: Carcinogenesis doi: 10.1093/carcin/bgt333 – year: 2014 ident: 10.1016/j.yexmp.2013.12.004_bb1000 article-title: Regulation of microRNA-1288 in colorectal cancer: Altered expression and its clinicopathological significance publication-title: Mol Carcinog. doi: 10.1002/mc.21993 – volume: 128 start-page: 132 year: 2011 ident: 10.1016/j.yexmp.2013.12.004_bb0135 article-title: Prognostic significance of differentially expressed miRNAs in esophageal cancer publication-title: Int. J. Cancer doi: 10.1002/ijc.25330 – volume: 44 start-page: 2204 year: 2013 ident: 10.1016/j.yexmp.2013.12.004_bb0300 article-title: Co-regulatory potential of vascular endothelial growth factor-A and vascular endothelial growth factor-C in thyroid carcinoma publication-title: Hum. Pathol. doi: 10.1016/j.humpath.2013.04.014 – volume: 47 start-page: 794 year: 2008 ident: 10.1016/j.yexmp.2013.12.004_bb0055 article-title: Deregulated expression of miR-106a predicts survival in human colon cancer patients publication-title: Genes Chromosomes Cancer doi: 10.1002/gcc.20580 – volume: 7 start-page: e42978 year: 2012 ident: 10.1016/j.yexmp.2013.12.004_bb0420 article-title: MicroRNA-126 inhibits tumor cell growth and its expression level correlates with poor survival in non-small cell lung cancer patients publication-title: PLoS One doi: 10.1371/journal.pone.0042978 – volume: 15 start-page: 272 year: 2008 ident: 10.1016/j.yexmp.2013.12.004_bb0080 article-title: miR-126 regulates angiogenic signaling and vascular integrity publication-title: Dev. Cell doi: 10.1016/j.devcel.2008.07.008 – volume: 345 start-page: 283 year: 2010 ident: 10.1016/j.yexmp.2013.12.004_bb0385 article-title: Differential miRNA expression and their target genes between NGX6-positive and negative colon cancer cells publication-title: Mol. Cell. Biochem. doi: 10.1007/s11010-010-0582-7 – volume: 130 start-page: 735 year: 2011 ident: 10.1016/j.yexmp.2013.12.004_bb0025 article-title: MicroRNA profiles of healthy basal and luminal mammary epithelial cells are distinct and reflected in different breast cancer subtypes publication-title: Breast Cancer Res. Treat. doi: 10.1007/s10549-010-1303-3 – volume: 23 start-page: 587 issue: 6 year: 2008 ident: 10.1016/j.yexmp.2013.12.004_bb0190 article-title: hTERT expression in colorectal adenocarcinoma: correlations with p21, p53 expressions and clinicopathological features publication-title: Int. J. Colorectal Dis. doi: 10.1007/s00384-008-0455-7 – volume: 7 start-page: e29671 year: 2012 ident: 10.1016/j.yexmp.2013.12.004_bb0060 article-title: MicroRNA signatures in tumor tissue related to angiogenesis in non-small cell lung cancer publication-title: PLoS One doi: 10.1371/journal.pone.0029671 – volume: 47 start-page: 939 year: 2008 ident: 10.1016/j.yexmp.2013.12.004_bb0095 article-title: The noncoding RNA, miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon cancers publication-title: Genes Chromosomes Cancer doi: 10.1002/gcc.20596 – volume: 12 start-page: 735 year: 2002 ident: 10.1016/j.yexmp.2013.12.004_bb0175 article-title: Identification of tissue-specific microRNAs from mouse publication-title: Curr. Biol. doi: 10.1016/S0960-9822(02)00809-6 – volume: 391 start-page: 1483 year: 2010 ident: 10.1016/j.yexmp.2013.12.004_bb0335 article-title: miR-126 inhibits non-small cell lung cancer cells proliferation by targeting EGFL7 publication-title: Biochem. Biophys. Res. Commun. doi: 10.1016/j.bbrc.2009.12.098 – volume: 22 start-page: 7950 year: 2003 ident: 10.1016/j.yexmp.2013.12.004_bb0260 article-title: Increased C-CRK proto-oncogene expression is associated with an aggressive phenotype in lung adenocarcinomas publication-title: Oncogene doi: 10.1038/sj.onc.1206529 – volume: 37 start-page: 93 year: 2011 ident: 10.1016/j.yexmp.2013.12.004_bb0305 article-title: Single nucleotide polymorphisms and mRNA expression of VEGF-A in papillary thyroid carcinoma: potential markers for aggressive phenotypes publication-title: Eur. J. Surg. Oncol. doi: 10.1016/j.ejso.2010.10.010 – volume: 585 start-page: 1191 year: 2011 ident: 10.1016/j.yexmp.2013.12.004_bb0255 article-title: miR-126 inhibits proliferation of small cell lung cancer cells by targeting SLC7A5 publication-title: FEBS Lett. doi: 10.1016/j.febslet.2011.03.039 – volume: 6 start-page: 445 year: 2012 ident: 10.1016/j.yexmp.2013.12.004_bb0110 article-title: Identification of recurrence-related microRNAs in hepatocellular carcinoma following liver transplantation publication-title: Mol. Oncol. doi: 10.1016/j.molonc.2012.04.001 – volume: 28 start-page: 4609 year: 2008 ident: 10.1016/j.yexmp.2013.12.004_bb0325 article-title: MicroRNA-126 regulates HOXA9 by binding to the homeobox publication-title: Mol. Cell. Biol. doi: 10.1128/MCB.01652-07 – volume: 206 start-page: 230 year: 2013 ident: 10.1016/j.yexmp.2013.12.004_bb0365 article-title: CRKL promotes cell proliferation in gastric cancer and is negatively regulated by miR-126 publication-title: Chem. Biol. Interact. doi: 10.1016/j.cbi.2013.09.003 – volume: 105 start-page: 15535 year: 2008 ident: 10.1016/j.yexmp.2013.12.004_bb0230 article-title: Distinct microRNA expression profiles in acute myeloid leukemia with common translocations publication-title: Proc. Natl. Acad. Sci. U. S. A. doi: 10.1073/pnas.0808266105 – volume: 96 start-page: 702 year: 2009 ident: 10.1016/j.yexmp.2013.12.004_bb0015 article-title: MicroRNAs are novel biomarkers of colorectal cancer publication-title: Br. J. Surg. doi: 10.1002/bjs.6628 – volume: 30 start-page: 651 year: 2013 ident: 10.1016/j.yexmp.2013.12.004_bb0040 article-title: Decreased expression of miR-126 correlates with metastatic recurrence of hepatocellular carcinoma publication-title: Clin. Exp. Metastasis doi: 10.1007/s10585-013-9569-6 – volume: 45 start-page: 2197 year: 2009 ident: 10.1016/j.yexmp.2013.12.004_bb0045 article-title: Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation publication-title: Eur. J. Cancer doi: 10.1016/j.ejca.2009.04.039 – volume: 39 start-page: 599 issue: 4 year: 2008 ident: 10.1016/j.yexmp.2013.12.004_bb0185 article-title: Aurora kinase expression in colorectal adenocarcinoma: correlations with clinicopathological features, p16 expression, and telomerase activity publication-title: Hum. Pathol. doi: 10.1016/j.humpath.2007.09.001 – volume: 34 start-page: 3871 year: 2013 ident: 10.1016/j.yexmp.2013.12.004_bb0410 article-title: MicroRNA-126 inhibits osteosarcoma cells proliferation by targeting Sirt1 publication-title: Tumour Biol. doi: 10.1007/s13277-013-0974-x – volume: 40 start-page: 25 issue: 1 year: 2008 ident: 10.1016/j.yexmp.2013.12.004_bb0310 article-title: Real-time PCR quantification of human telomerase reverse transcriptase (hTERT) in colorectal cancer publication-title: Pathology doi: 10.1080/00313020701716425 – volume: 85 start-page: 331 year: 2010 ident: 10.1016/j.yexmp.2013.12.004_bb0035 article-title: Differential expression of specific microRNA and their targets in acute myeloid leukemia publication-title: Am. J. Hematol. doi: 10.1002/ajh.21667 |
| SSID | ssj0009012 |
| Score | 2.429433 |
| SecondaryResourceType | review_article |
| Snippet | miR-126 has been implicated in the processes of inflammation and angiogenesis. Through these processes, miR-126 is implicated in cancer biology, but its role... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 98 |
| SubjectTerms | Biomarkers, Tumor - genetics Cancer Carcinoma Humans MicroRNAs - genetics miR-126 Neoplasms - diagnosis Neoplasms - genetics Neoplasms - therapy |
| Title | miR-126 in human cancers: Clinical roles and current perspectives |
| URI | https://dx.doi.org/10.1016/j.yexmp.2013.12.004 https://www.ncbi.nlm.nih.gov/pubmed/24368110 https://www.proquest.com/docview/1511821752 |
| Volume | 96 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8QwEB5EQb2Ib9cXETxaNY-mrbdlUVYXPYiit5BNUlhZ6-KuoBd_u5k0VQT14KlQGhpm0sk3nS_fAOwzn1VYXppEZ6VOhKU60U4Kn6WYwodCaYvAJry8kt1bcXGf3k9BpzkLg7TKGPvrmB6idbxzFK15NBoM8IyvTwbyUHrDtB3zdiEy1M8_fP-iefj9rlYMpyLBpxvlocDxenOvjyhaSXn4Jxi7tf2wO_2GPsMudLYICxE-knY9wyWYctUyzHWarm3LMHsZi-Ur0H4cXCeUSTKoSGjFRwy6-Hl8QqIa6JAguXBMdGWJqYWayOjr9OV4FW7OTm863SR2TEiM__YmiUdXhTMe4mhqPQ7o037JsjTlGSslt1xoLV2B5VyZW36sNaUyF85wl9s897nqGkxXT5XbAJLx3JS5w8KoFNoVRcqcTIsi085m3JoWsMZQykQ1cWxqMVQNbexBBesqtK6iTHnrtuDgc9CoFtP4-3HZeEB9WxPKh_u_B-41_lLe_FgC0ZV7ehkrGhIqD5lYC9ZrR37OhKEYv0dDm_997RbMM1xmgdO9DdOT5xe34yHLpL8b1uQuzLTPe90rvPau73ofK3_pJg |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8QwEB5EwfUivl2fETxaNUmbtt5kUdbH7kFW2FvIJimsaF3cFfTib3eSpiuCevBaEhpmppNvOjPfABwyjCoML3Sk0kJFsaEqUlbEGKXoHF2hMLmvJux0Rfs-vu4n_Rlo1b0wrqwy-P7Kp3tvHZ6cBGmejIZD1-OLwUDmU28ubMe4fS5OeOpM-_jjq84DL7yKMpzGkVteUw_5Iq93-_bkWCsp9z8Fw7i2H66n3-Cnv4Yul2Ax4EdyXh1xGWZsuQKNVj22bQXmOyFbvgrnT8O7iDJBhiXxs_iIdjp-GZ-RQAf6SFx14Zio0hBdMTWR0Vf75XgNepcXvVY7CiMTIo0f3yRCeJVbjRhHUYNAYEAHBUsTlAorBDc8VkrY3OVzRWb4qVKUiiy2mtvMZBkGq-swWz6XdhNIyjNdZNZlRkWsbJ4nzIokz1NlTcqNbgKrBSV1oBN3Uy0eZV039iC9dKWTrqRMonSbcDTdNKrYNP5eLmoNyG9GIdHf_73xoNaXRPG7HIgq7fPrWFIfUSFmYk3YqBQ5PQlzbPwIh7b--9p9aLR7nVt5e9W92YYF5kzOF3jvwOzk5dXuIn6ZDPa8fX4CWzDpGQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=miR-126+in+human+cancers%3A+clinical+roles+and+current+perspectives&rft.jtitle=Experimental+and+molecular+pathology&rft.au=Ebrahimi%2C+Faeza&rft.au=Gopalan%2C+Vinod&rft.au=Smith%2C+Robert+Anthony&rft.au=Lam%2C+Alfred+King-Yin&rft.date=2014-02-01&rft.issn=1096-0945&rft.eissn=1096-0945&rft.volume=96&rft.issue=1&rft.spage=98&rft_id=info:doi/10.1016%2Fj.yexmp.2013.12.004&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0014-4800&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0014-4800&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0014-4800&client=summon |